These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34106908)

  • 1. FLT3 inhibitors in acute myeloid leukemia: increasing options.
    Kadia TM
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):352-355. PubMed ID: 34106908
    [No Abstract]   [Full Text] [Related]  

  • 2. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 3. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.
    Lou YJ
    Acta Pharmacol Sin; 2012 Feb; 33(2):212-3. PubMed ID: 22231396
    [No Abstract]   [Full Text] [Related]  

  • 5. Emergence of crenolanib for FLT3-mutant AML.
    Fathi AT
    Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
    Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY
    Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Fesler MJ; Richart JM; Petruska PJ
    Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
    [No Abstract]   [Full Text] [Related]  

  • 9. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in FLT3 inhibitors for acute myeloid leukemia.
    Tong L; Li X; Hu Y; Liu T
    Future Med Chem; 2020 May; 12(10):961-981. PubMed ID: 32314599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FLT3 inhibitor monotherapy for refractory acute myeloid leukemia: a case report].
    Pan J; Yang JF; Tong CR
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Nov; 16(11):1168-9. PubMed ID: 25406566
    [No Abstract]   [Full Text] [Related]  

  • 16. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
    Langdon WY
    Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
    Fathi AT; Chen YB
    Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 20. Closing in on targeted therapy for acute myeloid leukaemia.
    The Lancet Haematology
    Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.